14/09/2026
Home in a day instead of weeks in recovery.
A study of 787 patients treated with laser interstitial thermal therapy (LITT) found survival depended heavily on how completely the laser destroyed the tumor. Patients with newly diagnosed glioblastoma who had at least 91% of their tumor ablated lived a median of 2.1 years, compared to just 0.36 years for those with 90% or less.
Unlike traditional open-skull surgery, LITT uses a small opening and a robotically guided laser probe, tracked by real-time MRI, to heat and destroy tumor cells. Median hospital stay was just 32.4 hours, and most patients avoided the ICU entirely.
Seizures dropped sharply too, from 54% of patients at baseline to 11% at six months in primary tumor cases. Risks remain real: 2.3% of patients had severe complications, and the surgical mortality rate was 0.25%.
Researchers say the findings help identify which patients benefit most, and that smaller, earlier-treated tumors may respond best.